Awards
2017 - 2018
Nominated for Gerald L. Logue Memorial Travel Award
Sponsor: Roswell Park Comprehensive Cancer Center,
Location: Buffalo, NY
2017
Best Poster, Annual Research Day
Sponsor: Jacobs School of Medicine and Biomedical Sciences
Location: University at Buffalo, Buffalo, NY
2014
Resident-Rock Award
Sponsor: Maimonides Medical Center
Location: Brooklyn, NY
2005
Dean's List in Basic Science Final Examinations
Sponsor: Kathmandu Medical College
Location: Nepal
2003 - 2009
Ministry of Education Scholarship
Sponsor: Kathmandu Medical College
Location: Nepal
VIEW ALL expand_more
Clinical Trials
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
Lead Researcher: Ajay Dhakal
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
View Study Details
An Open-Label Phase II Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
Lead Researcher: Ajay Dhakal
The purpose of this research is to look at the safety and effectiveness of a HER2-targeted therapy neratinib when given with capecitabine, a chemotherapy, for breast cancer patients with brain metastases whose tumors were HER2-negative by standard tests but showed abnormal HER2 activity based on the CELsignia results.
View Study Details
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Lead Researcher: Ajay Dhakal
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
View Study Details
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Lead Researcher: Ajay Dhakal
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
View Study Details
MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)
Lead Researcher: Ajay Dhakal
The purpose of this registry is to create a large-scale, population-based database. This
database will match health information to genome data to identify new gene associations in
breast cancer. The study will look at Agendia Breast Cancer tests, including MammaPrint® and BluePrint™, which
are tests that help doctors analyze and profile breast cancer tumors.
View Study Details